2024 Q2 Form 10-Q Financial Statement
#000149315224019535 Filed on May 15, 2024
Income Statement
| Concept | 2024 Q2 | 2024 Q1 | 2023 Q1 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Cost Of Revenue | |||
| YoY Change | |||
| Gross Profit | |||
| YoY Change | |||
| Gross Profit Margin | |||
| Selling, General & Admin | $1.094M | $1.215M | $1.302M |
| YoY Change | 14.08% | -6.68% | -11.43% |
| % of Gross Profit | |||
| Research & Development | $1.417M | $1.169M | $1.617M |
| YoY Change | 3.81% | -27.71% | -5.22% |
| % of Gross Profit | |||
| Depreciation & Amortization | $14.00K | $28.00K | $25.00K |
| YoY Change | -46.15% | 12.0% | 19.05% |
| % of Gross Profit | |||
| Operating Expenses | $1.417M | $1.169M | $1.617M |
| YoY Change | 3.81% | -27.71% | -49.09% |
| Operating Profit | -$2.511M | -$2.384M | -$2.919M |
| YoY Change | 8.05% | -18.33% | -8.09% |
| Interest Expense | $46.00K | $13.00K | $66.00K |
| YoY Change | 24.32% | -80.3% | -607.69% |
| % of Operating Profit | |||
| Other Income/Expense, Net | |||
| YoY Change | |||
| Pretax Income | -$2.465M | -$2.371M | -$2.853M |
| YoY Change | 7.78% | -16.89% | -10.54% |
| Income Tax | |||
| % Of Pretax Income | |||
| Net Earnings | -$2.465M | -$2.371M | -$2.853M |
| YoY Change | 7.78% | -16.89% | -10.54% |
| Net Earnings / Revenue | |||
| Basic Earnings Per Share | -$0.17 | -$0.17 | -$0.36 |
| Diluted Earnings Per Share | -$0.17 | -$0.17 | -$0.36 |
| COMMON SHARES | |||
| Basic Shares Outstanding | 14.40M shares | 14.40M shares | 8.131M shares |
| Diluted Shares Outstanding | 14.85M shares | 14.06M shares | 8.013M shares |
Balance Sheet
| Concept | 2024 Q2 | 2024 Q1 | 2023 Q1 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $6.462M | $6.349M | $5.057M |
| YoY Change | -34.86% | 25.55% | -59.45% |
| Cash & Equivalents | $2.465M | $1.162M | $2.150M |
| Short-Term Investments | $3.997M | $5.187M | $2.907M |
| Other Short-Term Assets | $524.0K | ||
| YoY Change | 85.82% | ||
| Inventory | |||
| Prepaid Expenses | |||
| Receivables | |||
| Other Receivables | |||
| Total Short-Term Assets | $7.138M | $7.000M | $5.581M |
| YoY Change | -30.96% | 25.43% | -56.23% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $122.0K | $132.0K | $196.0K |
| YoY Change | -32.22% | -32.65% | -78.92% |
| Goodwill | |||
| YoY Change | |||
| Intangibles | |||
| YoY Change | |||
| Long-Term Investments | |||
| YoY Change | |||
| Other Assets | |||
| YoY Change | |||
| Total Long-Term Assets | $296.0K | $367.0K | $627.0K |
| YoY Change | -45.69% | -41.47% | -32.58% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $7.138M | $7.000M | $5.581M |
| Total Long-Term Assets | $296.0K | $367.0K | $627.0K |
| Total Assets | $7.434M | $7.367M | $6.208M |
| YoY Change | -31.7% | 18.67% | -54.63% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $178.0K | $96.00K | $224.0K |
| YoY Change | -25.83% | -57.14% | 5.66% |
| Accrued Expenses | $1.053M | $896.0K | $743.0K |
| YoY Change | 22.58% | 20.59% | -49.21% |
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Long-Term Debt Due | |||
| YoY Change | |||
| Total Short-Term Liabilities | $1.341M | $1.183M | $1.233M |
| YoY Change | 1.28% | -4.06% | -26.39% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Other Long-Term Liabilities | $38.00K | $17.00K | $127.0K |
| YoY Change | -58.7% | -86.61% | -67.1% |
| Total Long-Term Liabilities | $38.00K | $17.00K | $127.0K |
| YoY Change | -58.7% | -86.61% | -67.1% |
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $1.341M | $1.183M | $1.233M |
| Total Long-Term Liabilities | $38.00K | $17.00K | $127.0K |
| Total Liabilities | $1.379M | $1.200M | $1.360M |
| YoY Change | -2.61% | -11.76% | -34.01% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$84.34M | -$81.87M | -$71.61M |
| YoY Change | 14.12% | 14.32% | |
| Common Stock | $90.39M | $88.04M | $76.46M |
| YoY Change | 8.42% | 15.14% | |
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | $6.055M | $6.167M | $4.848M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $7.434M | $7.367M | $6.208M |
| YoY Change | -31.7% | 18.67% | -54.63% |
Cashflow Statement
| Concept | 2024 Q2 | 2024 Q1 | 2023 Q1 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$2.465M | -$2.371M | -$2.853M |
| YoY Change | 7.78% | -16.89% | -10.54% |
| Depreciation, Depletion And Amortization | $14.00K | $28.00K | $25.00K |
| YoY Change | -46.15% | 12.0% | 19.05% |
| Cash From Operating Activities | -$1.957M | -$2.420M | -$3.203M |
| YoY Change | 5.56% | -24.45% | 6.52% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | $4.000K | $14.00K | |
| YoY Change | -60.0% | ||
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | $1.190M | $2.883M | |
| YoY Change | -192.61% | ||
| Cash From Investing Activities | $1.186M | -$1.284M | $2.883M |
| YoY Change | -191.58% | -144.54% | -18118.75% |
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | |||
| YoY Change | |||
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | 2.074M | $2.397M | |
| YoY Change | -69.13% | ||
| NET CHANGE | |||
| Cash From Operating Activities | -1.957M | -$2.420M | -$3.203M |
| Cash From Investing Activities | 1.186M | -$1.284M | $2.883M |
| Cash From Financing Activities | 2.074M | $2.397M | |
| Net Change In Cash | 1.303M | -$1.307M | -$320.0K |
| YoY Change | -63.5% | 308.44% | -89.41% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$1.957M | -$2.420M | -$3.203M |
| Capital Expenditures | $4.000K | $14.00K | |
| Free Cash Flow | -$1.961M | -$2.434M | -$3.203M |
| YoY Change | 5.2% | -24.01% | 7.09% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2023Q1 | MBOT |
Issuance Of Common Stock Value Upon Exercise Of Warrants
IssuanceOfCommonStockValueUponExerciseOfWarrants
|
usd | |
| CY2024Q1 | MBOT |
Interest Income And Unrealized Gains From Marketable Securities Net
InterestIncomeAndUnrealizedGainsFromMarketableSecuritiesNet
|
usd | |
| CY2023Q1 | MBOT |
Increase Decrease In Legal Settlement And Legal Expenses Received In Cash
IncreaseDecreaseInLegalSettlementAndLegalExpensesReceivedInCash
|
usd | |
| CY2023Q1 | MBOT |
Increase Decrease In Legal Settlement
IncreaseDecreaseInLegalSettlement
|
usd | |
| CY2023Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
usd | |
| CY2024Q1 | us-gaap |
Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
|
usd | |
| CY2023Q1 | us-gaap |
Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
|
usd | |
| CY2023Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
usd | |
| CY2023Q1 | us-gaap |
Stock Issued1
StockIssued1
|
usd | |
| CY2023Q1 | MBOT |
Accrual Bonus Settled Through Grant Of Stockoption Awards
AccrualBonusSettledThroughGrantOfStockoptionAwards
|
usd | |
| CY2024Q1 | dei |
Document Type
DocumentType
|
10-Q | |
| CY2024Q1 | dei |
Document Quarterly Report
DocumentQuarterlyReport
|
true | |
| CY2024Q1 | dei |
Document Period End Date
DocumentPeriodEndDate
|
2024-03-31 | |
| CY2024Q1 | dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2024 | |
| CY2024Q1 | dei |
Document Transition Report
DocumentTransitionReport
|
false | |
| CY2024Q1 | dei |
Entity File Number
EntityFileNumber
|
000-19871 | |
| CY2024Q1 | dei |
Entity Registrant Name
EntityRegistrantName
|
MICROBOT MEDICAL INC. | |
| CY2024Q1 | dei |
Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
|
DE | |
| CY2024Q1 | dei |
Entity Tax Identification Number
EntityTaxIdentificationNumber
|
94-3078125 | |
| CY2024Q1 | dei |
Entity Address Address Line1
EntityAddressAddressLine1
|
288 Grove Street | |
| CY2024Q1 | dei |
Entity Address Address Line2
EntityAddressAddressLine2
|
Suite 388 | |
| CY2024Q1 | dei |
Entity Address City Or Town
EntityAddressCityOrTown
|
Braintree | |
| CY2024Q1 | dei |
Entity Address State Or Province
EntityAddressStateOrProvince
|
MA | |
| CY2024Q1 | dei |
Entity Address Postal Zip Code
EntityAddressPostalZipCode
|
02184 | |
| CY2024Q1 | dei |
City Area Code
CityAreaCode
|
(781) | |
| CY2024Q1 | dei |
Local Phone Number
LocalPhoneNumber
|
875-3605 | |
| CY2024Q1 | dei |
Security12b Title
Security12bTitle
|
Common Stock | |
| CY2024Q1 | dei |
Trading Symbol
TradingSymbol
|
MBOT | |
| CY2024Q1 | dei |
Security Exchange Name
SecurityExchangeName
|
NASDAQ | |
| CY2024Q1 | dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | |
| CY2024Q1 | dei |
Entity Interactive Data Current
EntityInteractiveDataCurrent
|
Yes | |
| CY2024Q1 | dei |
Entity Filer Category
EntityFilerCategory
|
Non-accelerated Filer | |
| CY2024Q1 | dei |
Entity Small Business
EntitySmallBusiness
|
true | |
| CY2024Q1 | dei |
Entity Emerging Growth Company
EntityEmergingGrowthCompany
|
false | |
| CY2024Q1 | dei |
Entity Shell Company
EntityShellCompany
|
false | |
| CY2024Q2 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
14398964 | shares |
| CY2024Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
1215000 | usd |
| CY2023Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
1302000 | usd |
| CY2024Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-2384000 | usd |
| CY2023Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-2919000 | usd |
| CY2024Q1 | us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
13000 | usd |
| CY2023Q1 | us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
66000 | usd |
| CY2024Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-2371000 | usd |
| CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-2853000 | usd |
| CY2024Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.17 | |
| CY2024Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.17 | |
| CY2023Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.36 | |
| CY2023Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.36 | |
| CY2024Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
14055973 | shares |
| CY2024Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
14055973 | shares |
| CY2023Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
8013295 | shares |
| CY2023Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
8013295 | shares |
| CY2022Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
7289000 | usd |
| CY2023Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
412000 | usd |
| CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-2853000 | usd |
| CY2023Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
4848000 | usd |
| CY2023Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
4501000 | usd |
| CY2023Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
4501000 | usd |
| CY2024Q1 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
2397000 | usd |
| CY2024Q1 | MBOT |
Issuance Of Common Stock Value Relating To Settlement Agreement
IssuanceOfCommonStockValueRelatingToSettlementAgreement
|
1111000 | usd |
| CY2024Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
529000 | usd |
| CY2024Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-2371000 | usd |
| CY2024Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
6167000 | usd |
| CY2024Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
6167000 | usd |
| CY2024Q1 | us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
333000 | usd |
| CY2024Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-2371000 | usd |
| CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-2853000 | usd |
| CY2024Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
28000 | usd |
| CY2023Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
25000 | usd |
| CY2023Q1 | MBOT |
Interest Income And Unrealized Gains From Marketable Securities Net
InterestIncomeAndUnrealizedGainsFromMarketableSecuritiesNet
|
27000 | usd |
| CY2024Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
453000 | usd |
| CY2023Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
412000 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
389000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-140000 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
|
-376000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
|
-900000 | usd |
| CY2024Q1 | MBOT |
Increase Decrease In Legal Settlement And Legal Expenses Received In Cash
IncreaseDecreaseInLegalSettlementAndLegalExpensesReceivedInCash
|
-1335000 | usd |
| CY2024Q1 | MBOT |
Increase Decrease In Legal Settlement
IncreaseDecreaseInLegalSettlement
|
-1100000 | usd |
| CY2024Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-2420000 | usd |
| CY2023Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-3203000 | usd |
| CY2024Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
14000 | usd |
| CY2024Q1 | us-gaap |
Payments To Acquire Held To Maturity Securities
PaymentsToAcquireHeldToMaturitySecurities
|
5120000 | usd |
| CY2023Q1 | us-gaap |
Payments To Acquire Held To Maturity Securities
PaymentsToAcquireHeldToMaturitySecurities
|
638000 | usd |
| CY2024Q1 | us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
1350000 | usd |
| CY2023Q1 | us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
1000000 | usd |
| CY2024Q1 | us-gaap |
Proceeds From Sale And Maturity Of Held To Maturity Securities
ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities
|
2500000 | usd |
| CY2023Q1 | us-gaap |
Proceeds From Sale And Maturity Of Held To Maturity Securities
ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities
|
2518000 | usd |
| CY2023Q1 | us-gaap |
Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
|
-3000 | usd |
| CY2024Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-1284000 | usd |
| CY2023Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
2883000 | usd |
| CY2024Q1 | us-gaap |
Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
|
2397000 | usd |
| CY2024Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
2397000 | usd |
| CY2024Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-1307000 | usd |
| CY2023Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-320000 | usd |
| CY2023Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
2517000 | usd |
| CY2022Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
2519000 | usd |
| CY2024Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
1210000 | usd |
| CY2023Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
2199000 | usd |
| CY2024Q1 | us-gaap |
Interest Paid Net
InterestPaidNet
|
40000 | usd |
| CY2023Q1 | us-gaap |
Interest Paid Net
InterestPaidNet
|
35000 | usd |
| CY2024Q1 | us-gaap |
Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
|
37000 | usd |
| CY2023Q1 | us-gaap |
Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
|
12000 | usd |
| CY2024Q1 | us-gaap |
Stock Issued1
StockIssued1
|
1111000 | usd |
| CY2024Q1 | MBOT |
Accrual Bonus Settled Through Grant Of Stockoption Awards
AccrualBonusSettledThroughGrantOfStockoptionAwards
|
76000 | usd |
| CY2024Q1 | us-gaap |
Nature Of Operations
NatureOfOperations
|
<p id="xdx_80A_eus-gaap--NatureOfOperations_zqGwsTTEHpbb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1 – <span id="xdx_82C_z4c73W6nBWy">GENERAL</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A. Description of business</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot Medical Inc. (the “Company”) is a pre-clinical medical device company specializing in the research, design, and development of next generation robotic endoluminal surgery devices targeting the minimally invasive surgery space. The Company is primarily focused on leveraging its micro-robotic technologies with the goal of redefining surgical robotics while improving surgical outcomes for patients.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company incorporated on <span id="xdx_901_edei--EntityIncorporationDateOfIncorporation_c20240101__20240331_z2Ecj5WOST85" title="Date of incorporation">August 2, 1988</span> in the State of Delaware under the name Cellular Transplants, Inc. The original Certificate of Incorporation was restated on February 14, 1992 to change the name of the Company to Cyto Therapeutics, Inc. On May 24, 2000, the Certificate of Incorporation as restated was further amended to change the name of the Company to StemCells, Inc.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 28, 2016, the Company consummated a transaction pursuant to an Agreement and Plan of Merger, dated August 15, 2016, with Microbot Medical Ltd., a private medical device company organized under the laws of the State of Israel (“Microbot Israel”). On the same day and in connection with the Merger, the Company changed its name from StemCells, Inc. to Microbot Medical Inc. On November 29, 2016, the Company’s common stock began trading on the Nasdaq Capital Market under the symbol “MBOT”.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company and its subsidiary are sometimes collectively referred to as the “Company” as the context may require.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B. Risk Factors</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Going Concern</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To date, the Company has not generated revenues from its operations. As of March 31, 2024, the Company had cash equivalents and marketable securities balance of approximately $<span id="xdx_902_eus-gaap--CashCashEquivalentsAndShortTermInvestments_iI_pn3n3_c20240331_zKAmHDUwxfz" title="Cash equivalents and marketable securities">6,349</span>, excluding restricted cash. Due to continuing research and development activities, the Company expects to continue to incur additional losses for the foreseeable future. The Company implemented a cost reduction program in May 2023, and consummated capital raises in May, June 2023 and in January 2024. The Company will seek to raise additional funds through future issuances of either debt and/or equity securities and possibly additional grants from the Israeli Innovation Authority and other government institutions. The Company’s ability to raise additional capital in the equity and debt markets is dependent on a number of factors, including, but not limited to, the market demand for the Company’s stock, which itself is subject to a number of development and business risks and uncertainties, as well as the uncertainty that the Company would be able to raise such additional capital at a price or on terms that are favorable to the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accordingly, these conditions raise substantial doubt about the Company’s ability to continue as a going concern.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">War in Israel</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 7, 2023, the State of Israel, where the Company’s operations are primarily based, suffered a surprise attack by hostile forces from Gaza, which led to the declaration by Israel of the “Iron Swords” military operation. This military operation and related activities are on-going as of the issuance date of these financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has considered various ongoing risks relating to the military operation and related matters, including:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">That some of the Company’s Israeli subcontractors, vendors, suppliers and other companies in which the Company relies, are currently only partially active, as instructed by the relevant authorities; and</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A slowdown in the number of international flights in and out of Israel.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is closely monitoring how the military operation and related activities could adversely effect its anticipated milestones and its Israel-based activities to support future clinical and regulatory milestones, including the Company’s ability to import materials that are required to construct the Company’s devices and to ship them outside of Israel. As of the filing date of the Quarterly Report on Form 10-Q of which these financial statements are a part, the Company has determined that there have not been any materially adverse effects on its business or operations, but it continues to monitor the situation, as any future escalation or change could result in a material adverse effect on the ability of the Company’s Israeli office to support the Company’s clinical and regulatory activities. The Company does not have any specific contingency plans in the event of any such escalation or change.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C. Unaudited Interim Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying unaudited interim consolidated financial statements have been prepared in accordance with U.S. GAAP for interim financial information and with the instructions to Form 10-Q and Article 10 of U.S. Securities and Exchange Commission (“SEC”) regulations. Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included (consisting only of normal recurring adjustments except as otherwise discussed).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating results for the three-month period ended March 31, 2024 are not necessarily indicative of the results that may be expected for the year ending December 31, 2024.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> | |
| CY2024Q1 | dei |
Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
|
1988-08-02 | |
| CY2024Q1 | us-gaap |
Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
|
6349000 | usd |
| CY2024Q1 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<p id="xdx_84B_eus-gaap--UseOfEstimates_zRoylOX1CNQ7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> <span id="xdx_866_zIYj1igJklzi">Use of estimates</span>:</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions pertaining to transactions and matters whose ultimate effect on the financial statements cannot precisely be determined at the time of financial statements preparation. Although these estimates are based on management’s best judgment, actual results may differ from these estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> | |
| CY2024Q1 | MBOT |
Net Sales Royalty Percentage
NetSalesRoyaltyPercentage
|
0.03 | pure |
| CY2022Q4 | MBOT |
Gross Proceeds From Cash Fee Percentage
GrossProceedsFromCashFeePercentage
|
0.070 | pure |
| CY2022Q4 | MBOT |
Gross Proceeds From Management Fee Percentage
GrossProceedsFromManagementFeePercentage
|
0.010 | pure |
| CY2024Q1 | us-gaap |
Litigation Settlement Amount Awarded To Other Party
LitigationSettlementAmountAwardedToOtherParty
|
2154000 | usd |
| CY2023Q4 | MBOT |
Settlement Agreement Liability
SettlementAgreementLiability
|
2211000 | usd |
| CY2023Q4 | MBOT |
Insurance Recoverable
InsuranceRecoverable
|
1335000 | usd |
| CY2023Q4 | us-gaap |
Loss Contingency Receivable
LossContingencyReceivable
|
1100000 | usd |
| CY2023 | us-gaap |
Legal Fees
LegalFees
|
235000 | usd |
| CY2023 | us-gaap |
Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
|
-1111000 | usd |
| CY2024Q1 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
14398964 | shares |
| CY2024Q1 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
14398964 | shares |
| CY2023Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
11707317 | shares |
| CY2023Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
11707317 | shares |
| CY2023Q4 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
2730000 | usd |
| CY2023Q4 | MBOT |
Agent Fees And Other Offering Expenses
AgentFeesAndOtherOfferingExpenses
|
333000 | usd |
| CY2024Q1 | MBOT |
Annual Bonus
AnnualBonus
|
99 | usd |
| CY2024Q1 | ecd |
Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
|
false | |
| CY2024Q1 | ecd |
Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
|
false | |
| CY2024Q1 | ecd |
Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
|
false | |
| CY2024Q1 | ecd |
Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
|
false |
